PRINCETON, N.J.--(BUSINESS WIRE)--
Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced three abstracts were selected for presentation at the third annual CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival. The prestigious program brings together leading stakeholders in the field to teach, learn and disseminate the latest cutting-edge information and research in cancer immunology and immunotherapy.
Two poster presentations will feature preliminary immune correlative data from the ADXS-PSA monotherapy treatment arm of Advaxis’ Phase 1/2 study in combination with KEYTRUDA® (pembrolizumab) in metastatic castration-resistant prostate cancer (mCRPC) patients. The third presentation will feature preclinical data with the company’s HPV-targeted immunotherapy, axalimogene filolisbac.
The poster presentation, “Gene expression profiles associated with stable disease in metastatic castration-resistant prostate cancer patients treated with ADXS-PSA immunotherapy,” will feature preliminary data identifying potential pharmacodynamic biomarkers of clinical response in mCRPC patients treated with ADXS-PSA monotherapy.
The second poster presentation, “Persistence of expanded TCRβ clonotypes is associated with clinical activity of ADXS-PSA immunotherapy in metastatic castration-resistant prostate cancer,” will focus on the stability of expanded T cell clones in mCRPC patients following treatment with ADXS-PSA monotherapy. The preliminary immune correlative data will be presented by Sandy Hayes, Ph.D., Senior Director of Research and Biomarker Lead at Advaxis.
The third poster presentation, “Identification of an intratumoral immune gene signature associated with tumor regression in an axalimogene filolisbac-treated murine HPV+ tumor model,” will include preclinical data regarding molecular biomarkers associated with tumor regression in a murine HPV+ tumor model. It will be presented by Rachelle Kosoff, Ph.D., Senior Scientist in Research at Advaxis.
“Our findings provide important insights into identifying those patients who are benefiting from these treatments,” said Dr. Hayes. “We’re pleased to share our findings with the rest of the community at the International Cancer Immunotherapy Conference as we continue our work to bring new treatment options to patients.”
The third annual International Cancer Immunotherapy Conference takes place in the city of Mainz near Frankfurt, Germany from Sept. 6 – 9, 2017, and is jointly sponsored by the Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI) and the American Association for Cancer Research (AACR). Presentations will cover all areas of inquiry in cancer immunology and immunotherapy, including: neoantigens and vaccines, novel mechanisms of immunosuppression and immune evasion, biomarkers, new checkpoint immunotherapies and the tumor microenvironment.
To learn more about Advaxis and its immunotherapy clinical programs, visit www.advaxis.com/clinical-trials.
About Advaxis, Inc.
Located in Princeton, N.J., Advaxis, Inc. is a late-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology™. Lm Technology, using bioengineered live attenuated Listeria monocytogenes (Lm) bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T cells directed against cancer antigens and neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis’ lead Lm Technology immunotherapies axalimogene filolisbac and ADXS-DUAL target HPV-associated cancers and are in clinical trials for invasive and metastatic cervical cancer, head and neck cancer and anal cancer. The FDA has granted axalimogene filolisbac orphan drug designation for each of these three clinical settings, as well as Fast Track designation for adjuvant therapy for HRLACC patients and a Special Protocol Assessment for the Phase 3 AIM2CERV trial in patients with high-risk locally advanced carcinoma of the cervix. Axalimogene filolisbac has also been classified as an advanced therapy medicinal product for the treatment of cervical cancer by the EMA’s CAT. Advaxis has two additional immunotherapy products: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2 expressing solid tumors, in human clinical development. In addition, Advaxis and Amgen are developing ADXS-NEO, an investigational cancer immunotherapy treatment designed to activate a patient's immune system to respond against the unique mutations, or neoepitopes, contained in and identified from each individual patient's tumor, with plans to enter the clinic in 2017.
Advaxis Forward-Looking Statement
This press release contains forward-looking statements, including, but not limited to, statements regarding Advaxis’ ability to develop the next generation of cancer immunotherapies, and the safety and efficacy of Advaxis’ proprietary immunotherapies. These forward-looking statements are subject to a number of risks including the risk factors set forth from time to time in Advaxis’ SEC filings including, but not limited to, its report on Form 10-K for the fiscal year ended October 31, 2016, which is available at http://www.sec.gov.
Any forward-looking statements set forth in this presentation speak only as of the date of this presentation. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law.
You are cautioned not to place undue reliance on any forward-looking statements.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA